je.st
news
Tag: mercks
Mercks Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-cancers Caused by Five Additional HPV Types, in Phase III Study
2013-11-04 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Immunogenicity non-inferior to GARDASIL for original four HPV types Merck expects to file Biologics License Application with U.S. FDA in 2013 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in the pivotal Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. Language: English Contact: Media:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: in
additional
study
iii
Merck's Departure Will Impact Taxes, Council Candidate Says
2013-10-06 09:54:54| Biotech - Topix.net
Merck's decision to leave Summit and consolidate in Kenilworth will impact our property taxes.
Tags: impact
council
taxes
candidate
Interim Data for Mercks MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Previously Treated Patients with Non-Small Cell Lung Cancer to be Presented at 15th World Conference on Lung Cancer
2013-10-01 19:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, confirmed today that interim data from the companys Phase IB expansion study (PN 001) evaluating the efficacy and safety of *MK-3475 in patients with refractory non-small cell lung cancer (NSCLC) is scheduled for presentation at the 15th World Conference on Lung Cancer on Oct. 29 at 4:15 p.m., (1:15 a.m. EDT), in Sydney, Australia. Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Data from Mercks Investigational Hepatitis C Treatment Portfolio to be Presented at the 64th American Association for the Study of Liver Diseases Annual Meeting
2013-10-01 16:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of data from studies evaluating the companys investigational oral chronic hepatitis C virus (HCV) treatments MK-5172 and MK-8742 at the 64th American Association for the Study of Liver Diseases Annual Meeting (AASLD). The meeting is scheduled to take place in Washington, D.C., Nov. 1-5, 2013. Language: English Contact: MerckMedia:Sarra Herzog, 908-423-6154orInvestor:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Mercks Durham Site Receives U.S. FDA Licensure for Varicella Bulk
2013-09-04 21:50:12| Merck.com - Corporate News
Dateline City: DURHAM, N.C. Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the companys site in Durham, N.C., for use in Mercks vaccines to protect against chickenpox and shingles. The approval will enable the site to produce bulk varicella supply for the U.S. and help boost Mercks overall global supply capabilities. In 2010, the site was approved to produce finished chickenpox vaccines. Language: English Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: site
bulk
receives
durham
Sites : [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] next »